This funding opportunity supports the development of Hereditary Hemorrhagic Telangiectasia (HHT) Centers aimed at reducing illness and death by expanding clinical care access, innovating diagnostic strategies, and creating a de-identified patient data registry to enhance understanding of HHT and its treatment outcomes.
Eligible applicants include state governments and any other entity types as clarified in additional eligibility information. The opportunity is open to a broad range of organizations.
